Year-over-year, this metric declined by 100.0%, from $3.46B to $0.00. This decline may warrant attention — for this metric, higher values are generally preferred.
High spending indicates a strong commitment to pipeline growth, though it carries significant execution and regulatory risk.
Acquired In-Process Research and Development (IPR&D) represents the cash paid to acquire research projects that have not...
A hallmark metric for pharmaceutical and biotech firms relying on external innovation.
cf_acquired_ipr_d| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.19B | $0.00 | $0.00 | -$1.19B | $0.00 | $0.00 | $0.00 | $3.46B | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | — | — | — | — | — | — | — | -100.0% | — | — | +100.0% | — | — | — | -100.0% | — | — | — |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | -100.0% | — | — | +389.9% | — | — | — | -100.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.